Personalized Treatment for Advanced Combined Liver Cancer
Part of Cancer, Digestive system clinical trials.
This study is for people with a rare and advanced liver cancer called combined hepatocellular cholangiocarcinoma (CHC). Doctors will use information from your tumor and health history to find the best treatment approach for your specific cancer type.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of a rare liver cancer called combined hepatocellular cholangiocarcinoma (CHC).
- Your cancer must be too advanced to be removed by surgery, or it has spread to other parts of your body. You may have had treatment before, like local therapy or systemic therapy.
- You need to have at least one tumor that can be measured on a scan (a 'measurable lesion').
- Your overall health must be fairly good (ECOG performance status of 0, 1, or 2), meaning you can care for yourself and are up and about more than half of the day.
- Your liver function must be Child-Pugh class A or B, meaning your liver is working reasonably well.
- You must not have had other cancers in the last five years (except some very low-risk types), no major bleeding within the last six months, no organ or bone marrow transplant in the last two years, and no active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (tremelimumab and durvalumab) with standard chemotherapy (gemcitabine and cisplatin) for a rare type of liver cancer that has spread or cannot be removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests a combination of two drugs, cadonilimab and capecitabine, given after surgery to remove a rare type of liver cancer that has both hepatocellular and cholangiocarcinoma features. The goal is to see if this treatment helps prevent the cancer from coming back.
This study looks at how well combining interventional treatments (like chemoembolization) with systemic therapies (like targeted drugs and immunotherapy) works for liver cancer in real-life patients. The goal is to find which combinations work best for different people.
This study tests a combination treatment for liver cancer that has not spread to other organs. It combines two procedures that deliver chemo directly to the liver (HAIC and TACE) with two medications (apatinib and camrelizumab) that help your immune system fight the cancer.
This trial tests a combination of two treatments for advanced liver cancer that cannot be removed by surgery. One treatment delivers chemotherapy directly to the tumor, and the other uses tiny beads to block the tumor's blood supply. This approach may help shrink tumors and slow the cancer's growth.
This study tests a combination of treatments for liver cancer that cannot be removed with surgery. It combines a procedure called TACE, which delivers chemo directly to the tumor, with drugs that boost your immune system and block cancer growth. This might help shrink tumors and slow the cancer.
Hear when a new Combined Hepatocellular-cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.